Frontage Holdings Corp
Frontage Holdings Corp has a liquidity position with a current ratio of 1.33, indicating moderate short-term liquidity. The company's cash and equivalents amount to $36.3 million, while its long-term debt stands at $127.6 million, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure. In terms of profitability, Frontage Holdings Corp reports a return on equity (ROE) of 1.96% and a return on assets (ROA) of 1.26%. These figures are below the industry median for ROE and ROA in the Biotechnology & Medical Research sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is distributed across two main geographic segments: North America and Europe, and the People's Republic of China (PRC). However, the financial data does not provide a breakdown of revenue by segment, making it difficult to assess the concentration of revenue in any particular region. Frontage Holdings Corp's revenue for the latest period is $256.7 million. While the company's outlook for the current fiscal year is not explicitly provided, the absence of analyst recommendations for a "buy" or "strong buy" suggests a neutral or cautious market sentiment. The company's growth trajectory is not clearly defined in the available data, and there is no indication of significant changes in revenue or profitability in the near term. The risk assessment for Frontage Holdings Corp indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for long-term debt. There is no indication of dilution pressure in the near term, as the number of shares outstanding has not changed between basic and diluted shares. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position.
Business. Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies, including bioequivalence clinical and chemical services.
Classification. Frontage Holdings Corp is classified in the Healthcare economic sector under the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.
- Frontage Holdings Corp has a conservative capital structure with a debt-to-equity ratio of 0.37.
- The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency and asset utilization.
- The company's liquidity position is moderate, with a current ratio of 1.33 and a negative net cash position after subtracting long-term debt.
- There is no indication of dilution pressure in the near term, as the number of shares outstanding has not changed between basic and diluted shares.
- The company's growth trajectory is not clearly defined in the available data, and there is no indication of significant changes in revenue or profitability in the near term.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.